ArticleAnnals of clinical microbiology and antimicrobials2012
Sensitization of Candida albicans biofilms to various antifungal drugs by cyclosporine A.
Article in Annals of clinical microbiology and antimicrobials, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 54 citations in OpenAlex.
- Carvacrol and Thymol, a Synergistic Antimicrobial Activity Against Bacterial and Candida Species.MicrobiologyOpen · 2025Article
- Genomics insights of candidiasis: mechanisms of pathogenicity and drug resistance.Frontiers in microbiology · 2025Review
- Propranolol Ameliorates the Antifungal Activity of Azoles in Invasive Candidiasis.Pharmaceutics · 2023Article
- Chemical mutagenesis and high throughput media optimization in3 Biotech · 2022Article
- Drug repurposing strategies in the development of potential antifungal agents.Applied microbiology and biotechnology · 2021Review
- A Screen for Small Molecules to TargetJournal of fungi (Basel, Switzerland) · 2020Article
- Review
- Article
- Antifungal Therapy: New Advances in the Understanding and Treatment of Mycosis.Frontiers in microbiology · 2017Review
- The calcineruin inhibitor cyclosporine a synergistically enhances the susceptibility of Candida albicans biofilms to fluconazole by multiple mechanisms.BMC microbiology · 2016Article
- Fungal Biofilms: In Vivo Models for Discovery of Anti-Biofilm Drugs.Microbiology spectrum · 2015Article
- Irreversible electropermeabilization of the human pathogen Candida albicans: an in-vitro experimental study.European biophysics journal : EBJ · 2015Article
- Synergistic combinations of antifungals and anti-virulence agents to fight against Candida albicans.Virulence · 2015Review
- In vitro interactions of calcineurin inhibitors with conventional antifungal agents against the yeast form of Penicillium marneffei.Mycopathologia · 2014Article
- Synthesis and antifungal activity in vitro of isoniazid derivatives against histoplasma capsulatum var. capsulatum.Antimicrobial agents and chemotherapy · 2014Article
- Recent insights into Candida albicans biofilm resistance mechanisms.Current genetics · 2013Review
- Applying insights from biofilm biology to drug development - can a new approach be developed?Nature reviews. Drug discovery · 2013Review
- Peptidyl-prolyl isomerase-B is involved inNPJ biofilms and microbiomesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBiofilms formed by Candida albicans are resistant towards most of the available antifungal drugs. Therefore, infections associated with Candida biofilms are considered as a threat to immunocompromised patients. Combinatorial drug therapy may be a good strategy to combat C. albicans biofilms.
methodsCombinations of five antifungal drugs- fluconazole (FLC), voriconazole (VOR), caspofungin (CSP), amphotericin B (AmB) and nystatin (NYT) with cyclosporine A (CSA) were tested in vitro against planktonic and biofilm growth of C. albicans. Standard broth micro dilution method was used to study planktonic growth, while biofilms were studied in an in vitro biofilm model. A chequerboard format was used to determine fractional inhibitory concentration indices (FICI) of combination effects. Biofilm growth was analyzed using XTT-metabolic assay.
resultsMICs of various antifungal drugs for planktonic growth of C. albicans were lowered in combination with CSA by 2 to 16 fold. Activity against biofilm development with FIC indices of 0.26, 0.28, 0.31 and 0.25 indicated synergistic interactions between FLC-CSA, VOR-CSA, CSP-CSA and AmB-CSA, respectively. Increase in efficacy of the drugs FLC, VOR and CSP against mature biofilms after addition of 62.5 μg/ml of CSA was evident with FIC indices 0.06, 0.14 and 0.37, respectively.
conclusionsThe combinations with CSA resulted in increased susceptibility of biofilms to antifungal drugs. Combination of antifungal drugs with CSA would be an effective prophylactic and therapeutic strategy against biofilm associated C. albicans infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.